Affymetrix Introduces Axiom Transplant Genotyping Array for Genomic Profiling of Immune-Related Markers
October 06 2015 - 5:30AM
Business Wire
Affymetrix (NASDAQ:AFFX) introduces Axiom® Transplant Genotyping
Array, designed in collaboration with an international team of
surgeons and scientists for research studies to improve
transplantation success and individualize donor/patient selection
and treatment. The array comprises ~ 780,000 markers, including
over 30,000 variants that may contribute to transplant rejection or
other complications. Researchers will also find the array useful in
the study of immunology, disease and drug treatments; meta-analyses
may be conducted, combining data with other genotype databases such
as the UK Biobank cohort, a collection of more than 500,000
volunteers genotyped using the Affymetrix UK Biobank Axiom
Array.
Currently, selecting donors whose human leukocyte antigen (HLA)
genes are a good match with transplant recipients via HLA molecular
typing is the standard of care. Research with this new transplant
array focuses on finding additional transplant-related variants
that will provide insight into early detection of graft-versus-host
disease as well as genomic markers associated with metabolism of
immunosuppressant drugs. In addition, Affymetrix Axiom HLA Analysis
software enables affordable, high-throughput, accurate analysis of
11 classical loci at 4-digit resolution by imputing HLA type from
Axiom array-generated genotype data.
“The combination of our high-fidelity Axiom array technology,
powerful Axiom™ Analysis Suite, Axiom™ HLA Analysis software, and
the ability to integrate patient data from the UK Biobank enables
transplant genomic profiling on a scale that has not been seen
before,” commented Laurent Bellon, Ph.D., senior vice president and
general manager, Genotyping Business Unit at Affymetrix. “The
application of these tools delivers a very cost-effective approach
that can propel discovery with the potential to improve patient
outcomes.”
Axiom Transplant Genotyping Array was developed and tested by
the International Genetics and Translational Research in
Transplantation Network (iGeneTRAiN), co-led by researchers from
the Perelman School of Medicine at the University of Pennsylvania.
The team published two peer-reviewed publications in October about
the project.
“The genetic datasets we’ve put together in this project are by
far the largest ever assembled in transplant genomics,” said
Brendan J. Keating, DPhil, a research assistant professor of
Transplant Surgery in the Perelman School of Medicine at the
University of Pennsylvania. “Prior to the development of this
array, it was not possible to look at all of these markers
together.”
Affymetrix contributed an additional set of ~350,000 SNPs for
Caucasian-European and non-European populations to improve the mean
coverage achieved in major ethnicities, including African and
Asian, as well as a significant amount of content from various
functional modules of the Axiom Genomic Database. These SNPs were
chosen with the goal of creating comprehensive overlap with
existing data being generated using UK Biobank Axiom Array and
Axiom Biobank Genotyping Array, to enable joint- or meta-analyses
of samples genotyped with these tools as well as other conventional
GWAS tools.
About Affymetrix
Affymetrix provides leadership and support, partnering with
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest to use biology for a better
world. More than 2,300 microarray systems have been shipped around
the world and more than 94,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, San Diego, Vienna, and Singapore.
Affymetrix has about 1,100 employees and maintains sales and
distribution operations worldwide. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Axiom, Affymetrix, and
the Affymetrix logo trademarks are the property
of Affymetrix, Inc. All other trademarks are the property
of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151006005705/en/
Affymetrix, Inc.Media:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestors:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024